NCT02722044View on ClinicalTrials.gov

Usability of an AI for M923 in Subjects With Moderate to Severe RA

PHASE3CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

February 21, 2017

Study Completion Date

February 21, 2017

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

M923

Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)

DEVICE

Autoinjector

Subcutaneous administration

Trial Locations (7)

16635

Altoona Center for Clinical Research, PC, Duncansville

27408

Medication Management, LLC, Greensboro

48202

Henry Ford Health System, Detroit

73112

Lynn Health Science Institute, Oklahoma City

77004

Accurate Clinical Management, Houston

77034

Accurate Clinical Research, Inc., Houston

78731

Austin Regional Clinic, PA, Austin

Sponsors
All Listed Sponsors
lead

Momenta Pharmaceuticals, Inc.

INDUSTRY